| Interacting proteins: O75015 and P02743 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: O75015 and P02743 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: O75015 and P02743 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: O75015 and P02743 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: O75015 and P02743 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: O75015 and P02743 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: O75015 and P02743 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: O75015 and P02743 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: O75015 and P02743 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: O75015 and P02743 |
Pubmed |
SVM Score :0.0 |
| In the present study we prospectively analyzed the serial effects of androgen replacement therapy on both the distribution of peripheral blood lymphocytes , monocytes and dendritic cells as well as on the production of interleukin ( IL ) 1beta , IL 6 and tumor necrosis factor alpha ( TNFalpha ) inflammatory cytokines by circulating monocytes and CD 33 myeloid , CD 16 and plasmacytoid dendritic cell subsets , the most potent antigen presenting cells ( APCs ) in type 2 diabetic men with partial androgen deficiency . ^^^ |
|